Safety of Converting From Tetrabenazine to Deutetrabenazine for the Treatment of Chorea

川芎嗪 舞蹈病 医学 药理学 心理治疗师 精神科 心理学 内科学 疾病 多巴胺
作者
Samuel Frank,David Stamler,Elise Kayson,Daniel O. Claassen,Amy Colcher,Charles S. Davis,Andrew P. Duker,Shirley Eberly,Lawrence Elmer,Erin Furr‐Stimming,Mark Gudesblatt,Christine Hunter,Joseph Jankovic,Sandra K. Kostyk,Rajeev Kumar,Clement T. Loy,William Mallonee,David Oakes,B.L. Scott,Victor Sung
出处
期刊:JAMA Neurology [American Medical Association]
卷期号:74 (8): 977-977 被引量:211
标识
DOI:10.1001/jamaneurol.2017.1352
摘要

Importance: Tetrabenazine is efficacious for chorea control; however, tolerability concerns exist. Deutetrabenazine, a novel molecule that reduces chorea, was well tolerated in a double-blind, placebo-controlled study. Objectives: To evaluate the safety and explore the efficacy of conversion from tetrabenazine to deutetrabenazine in patients with chorea associated with Huntington disease (HD). Design, Setting, and Participants: In this ongoing, open-label, single-arm study that started on December 21, 2013, 37 patients at 13 Huntington Study Group sites in the United States and Australia who were taking stable doses of tetrabenazine that provided a therapeutic benefit were switched overnight to deutetrabenazine therapy. After week 1, the deutetrabenazine dose was titrated on a weekly basis for optimal chorea control. Interventions: Deutetrabenazine administration at a dosage thought to provide comparable systemic exposure to the active metabolites of the prior, stable tetrabenazine regimen. Main Outcomes and Measures: Safety measures included adverse events (AEs), clinical laboratory tests, vital signs, electrocardiograms, and validated scales. Changes in the Unified Huntington's Disease Rating Scale total maximal chorea score and total motor score were efficacy end points. Results: Of the 53 patients with HD screened for the study, 37 ambulatory patients with manifest HD (mean [SD] age, 52.4 [11.5] years; 22 [59%] male and 15 [41%] female; 36 white [97.3%]) were enrolled. Deutetrabenazine was generally well tolerated, with low rates of neuropsychiatric AEs. Safety scales did not reveal subclinical toxicity with deutetrabenazine treatment. Rates of dose reduction or suspension attributable to AEs were also low. Chorea control, as measured by the total maximal chorea score, was maintained at week 1 and significantly improved at week 8 (mean [SD] change from baseline, 2.1 [3.2]; P < .001). Conclusions and Relevance: In patients with chorea, overnight conversion to deutetrabenazine therapy provided a favorable safety profile and effectively maintained chorea control.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
湖北第一帅完成签到,获得积分10
刚刚
1秒前
canhui发布了新的文献求助10
1秒前
科研通AI6.4的应助被ch采纳,获得30
1秒前
canhui发布了新的文献求助10
1秒前
canhui发布了新的文献求助10
2秒前
canhui发布了新的文献求助10
2秒前
canhui发布了新的文献求助10
2秒前
canhui发布了新的文献求助10
2秒前
canhui发布了新的文献求助10
2秒前
2秒前
2秒前
3秒前
K神完成签到,获得积分10
3秒前
3秒前
朱帅发布了新的文献求助10
4秒前
Jupiter发布了新的文献求助10
4秒前
5秒前
5秒前
canhui发布了新的文献求助10
5秒前
canhui发布了新的文献求助10
5秒前
canhui发布了新的文献求助10
5秒前
拼搏的依风完成签到 ,获得积分10
5秒前
canhui发布了新的文献求助10
5秒前
6秒前
6秒前
7秒前
伶俐飞风发布了新的文献求助10
7秒前
一眼顶针发布了新的文献求助10
8秒前
canhui发布了新的文献求助30
8秒前
8秒前
CarryLJR的应助被111111ww采纳,获得10
9秒前
canhui发布了新的文献求助10
9秒前
9秒前
canhui发布了新的文献求助10
9秒前
canhui发布了新的文献求助10
9秒前
10秒前
10秒前
10秒前
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8178484
求助须知:如何正确求助?哪些是违规求助? 9569318
关于积分的说明 21803439
捐赠科研通 7773381
什么是DOI,文献DOI怎么找? 3432819
关于科研通互助平台的介绍 2556838
邀请新用户注册赠送积分活动 2478441